07:00 , Apr 11, 2011 |  BC Week In Review  |  Financial News

Aldagen withdraws IPO

Aldagen Inc. , Durham, N.C.   Business: Gene/Cell therapy   Date announced: 4/5/11   Type: IPO   Underwriters: Boenning & Scattergood Inc.; Ladenburg Thalmann; National Securities   Note: Aldagen withdrew its IPO due to market...
08:00 , Jan 31, 2011 |  BC Week In Review  |  Financial News

Iaso Pharma amends IPO

Iaso Pharma Inc. , San Diego, Calif.   Business: Infectious   Date announced: 1/21/11   Type: IPO   To be raised: Up to $23 million   Shares: 4 million   Price: $4.50-$5.50   Underwriters: Ladenburg...
07:00 , Jul 5, 2010 |  BC Week In Review  |  Financial News

Aldagen amends IPO

Aldagen Inc. , Durham, N.C.   Business: Gene/Cell therapy   Date announced: 7/2/10   Type: IPO   To be raised: Up to $40 million   Price: TBD   Underwriter: Boenning & Scattergood Inc.; Ladenburg Thalmann;...
07:00 , May 24, 2010 |  BC Week In Review  |  Financial News

RegeneRx completes follow-on

RegeneRx Biopharmaceuticals Inc. (NYSE-A:RGN), Rockville, Md.   Business: Dermatology, Ophthalmic, Cardiovascular   Date completed: 5/18/10   Type: Follow-on   Raised: $4.7 million   Units: 11.5 million   Price: $0.41 (unit)   Shares after offering: 71.9...
07:00 , May 10, 2010 |  BC Week In Review  |  Financial News

Aldagen amends IPO

Aldagen Inc. , Durham, N.C.   Business: Gene/Cell therapy   Date announced: 5/5/10   Type: IPO   To be raised: Up to $80.5 million   Price: TBD   Underwriters: Boenning & Scattergood Inc.; Ladenburg Thalmann;...
08:00 , Dec 14, 2009 |  BC Week In Review  |  Financial News

Aldagen amends IPO

Aldagen Inc. , Durham, N.C.   Business: Gene/Cell therapy   Date announced: 12/10/09   Type: IPO   To be raised: Up to $80.5 million   Price: TBD   Shares: TBD   Underwriters: Cowen; Wells Fargo;...
08:00 , Feb 16, 2009 |  BC Week In Review  |  Company News

Ambrilia cancer, infectious news

Ambrilia retained Boenning & Scattergood Inc. to review strategic alternatives. The company also said it has completed its previously announced headcount reductions, including its CSO and Senior EVP Bonabes de Rouge. Ambrilia now has 15...
07:00 , Oct 27, 2008 |  BC Week In Review  |  Company News

Chemokine Therapeutics cancer, hematology, cardiovascular news

Chemokine hired Boenning & Scattergood Inc. to evaluate strategic options including merger, sale, licensing and partnership transactions. Chemokine's CTCE-9908, a peptide analog of chemokine CXC motif ligand 12 (CXCL12) (SDF-1) and CXC chemokine receptor 4...